Clover Corporation Limited (CLV) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and thanks very much for joining us. Welcome to the Clover Corporation FY25 results presentation. My name is Peter Davey and I'm the Managing Director and CEO of Clover. And with me is Andrew Allibon. Andrew is the CFO and Company Secretary. And we are very pleased to be taking you through some very good results. So it's lovely to be talking to you again this year. The first slide takes us just a bit of an overview of the company. Clover is a global leader in the microencapsulation of Omega-3s and we service the infant formula and food market. We are in infant formula, we are in functional food and beverage and pharmaceuticals and supplements and certainly over the last 12 to 18 months we've seen a significant differentiation of our products into alternative markets. Our manufacturing footprint is across Australia, New Zealand and Ecuador and later in the presentation I'll talk you through our vertical integration strategy and how that's servicing the business. We have just over 68 employees and we use vertical integration of the business into other suppliers that provide us with a lot of services so it's a fairly light business in terms of the amount of employees we have. We have 22 different products. We have 81 patents, which is a pretty fabulous thing for a relatively small Australian company. And we service over 40 countries in the world. So we are truly a global organization with 99% of the products that we manufacture in Australia exported overseas. It's very pleasing to turn to the results for FY25. We've had a really strong year across all metrics for the business. The revenue position for the year ended at $86 million. That's up 38% on the prior year, which was 62.2%. Really, an interesting conundrum of the year was really the variance in first...